[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ldl-cholesterol\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ldl-cholesterol":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,56,85,117,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":37,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100643083","effectiveness-of-neomayor-in-improving-cardiovascular-health-100643083",false,"NCT07633392","Effectiveness of NeoMayor in Improving Cardiovascular Health","Effectiveness of NeoMayor in Improving Cardiovascular Health Status in Chilean Adults","NEOMAYOR","Inclusion criteria\n\n* Age between 55 and 75 years\n* Able to read and understand written instructions\n* Ownership of a smartphone and ability to use it independently\n* Physically inactive, defined as performing less than 30 minutes of daily physical activity or less than 2,5 h a week).\n* Intermediate or high cardiovascular risk, defined as the presence of at least three of the following: Hypertension (history diagnosed by specialist or general practitioner or ≥ 140 mmHg systolic or ≥90 mm Hg diastolic blood pressure at baseline or current antihypertensive treatment);Diabetes Mellitus (history diagnosed by specialist or general practitioner or fasting blood glucose ≥126 mg\u002FdL or current pharmacologic treatment);Obesity (BMI ≥30 kg\u002Fm²); Dyslipidaemia (history diagnosed by specialist or general practitioner or lipid-lowering drugs or baseline total cholesterol ≥ 200 mg\u002FdL or LDL cholesterol ≥100 mg\u002FdL).\n\nExclusion Criteria\n\n* Dementia defined as a score in the Mini-ACE \\\u003C 21\n* Significant limitations for independent mobility, including use of assistive devices, frailty, gait instability, or lower-limb painful conditions limiting physical activity\n* Uncorrected hearing or visual impairment preventing adequate use of a smartphone\n* Chronic neurological, psychiatric, or psychological disorders without regular treatment or follow-up.\n* Present severe alcohol or illicit drug use.\n* Severe or terminal illness.","ALL","55 Years","75 Years",{"count":21,"type":22},240,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to evaluate the effectiveness of NeoMayor, a mobile health (mHealth) intervention designed to improve cardiovascular health among older adults at elevated cardiovascular risk in Chile. NeoMayor is a smartphone-based application that provides personalized guidance on physical activity, diet, sleep, and mental well-being through a multidomain lifestyle approach.\n\nThis multicenter randomized controlled trial will enroll community-dwelling older adults aged 55 to 75 years recruited from primary healthcare centers in urban and rural settings. Participants will be randomized in a 2:1 ratio to either the NeoMayor intervention or a control group receiving standard health information and usual care. The intervention duration will be four months.\n\nThe primary objective is to determine whether the NeoMayor intervention improves cardiovascular health as measured by the Life's Essential 8 Cardiovascular Health Index. Secondary objectives include evaluating changes in cognitive performance, depressive symptoms, anxiety symptoms, quality of life and physical performance outcomes. The study will also assess feasibility and adherence to digital intervention.",[28,29,30,31,32,33,34,35,36],"Cardiovascular Health Status","Smoking Status","Physical Activity","Diet Quality","Sleep Duration","Body Mass Index","Blood Pressure","LDL Cholesterol","Fasting Glucose",[38,39,40,41,42],"Cardiovascular Health Index","cardiovascular risk","Life's Essential 8","mhealth","older adults","NOT_YET_RECRUITING","2026-06-12",{"date":46,"type":47},"2026-06-16","ACTUAL",{"date":49,"type":22},"2026-09-01",{"date":51,"type":22},"2027-05",{"name":53,"class":54},"University of Chile","OTHER",2,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":17,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":23,"phases":68,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":55},"100598414","effects-of-milk-based-drinks-on-gut-microbiome-sleep-and-cardiometabolic-markers-100598414","NCT07071181","Effects of Milk-based Drinks on Gut Microbiome, Sleep and Cardiometabolic Markers","A Randomised, Double-blind Trial to Measure the Effects of Milk-based Drinks on Gut Microbiome, Sleep, and Cardiometabolic Markers in Adults With Poor Sleep","Inclusion Criteria:\n\n* Aged 40-70 years old\n* Suffer with poor sleep (measured using the PIttsburg Sleep Quality Index with a score \\> 5)\n* BMI in range of 25-35 kg\u002Fm2\n* Willingness to consume each study drink daily for 4 weeks and attend the laboratory on 4 separate occasions\n* For women: Medication in the form of contraception or HRT providing these have not been modified 3 months prior to the first study day\n\nExclusion Criteria:\n\n* Intolerance or allergy to milk-based products\n* Pregnancy\u002Fbreastfeeding\n* Insufficient English language skills to complete all study questionnaires and perform the cognitive tests\n* Gastrointestinal disorders\n* Inability to attend the laboratory due to travel\u002Fmobility difficulties",true,"40 Years","70 Years",{"count":67,"type":22},40,[25],"The purpose of this study is to evaluate the effects of kefir on gastrointestinal health, sleep quality, and biochemical parameters in adults who have sleep problems. Further measurements of cognitive function, arterial stiffness and blood pressure will also be assessed.\n\nThe following questions will be addressed during the study:\n\n1. What effect does repeated ingestion of kefir have on the gut microbiome and can this positively influence sleep performance (quality and duration) in adults with sleep problems?\n2. Does repeated ingestion of kefir impact LDL, triacyglycerols and non-HDLc in adults with sleep problems?\n3. What effect does repeated ingestion of kefir have on cognitive function and mood?\n4. What effect does repeated ingestion of kefir have on vascular function, inflammation and markers of immunity in adults with sleep problems?\n\nIn a randomised, crossover design study, participants will consume 250 ml of kefir (original flavour) or milk for 4 weeks with a 4-week washout.",[71,72,73,74,35],"Sleep","Cardiovascular Diseases","Gut Microbiome","Cognitive Function and Mood","RECRUITING","2025-07-09",{"date":78,"type":47},"2025-07-17",{"date":80,"type":22},"2025-08",{"date":82,"type":22},"2026-03",{"name":84,"class":54},"Sheffield Hallam University",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":103,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100564203","efficacy-of-lipid-lowering-therapy-based-on-apolipoprotein-b-versus-ldl-cholesterol-levels-in-patients-undergoing-percutaneous-coronary-intervention-100564203","NCT06626126","Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention","Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention: a Multicenter, Randomized Controlled Trial","ApoB-guidedLLT","Inclusion Criteria:\n\n1. Patients aged 18 years or older.\n2. Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).\n3. Patients who agree to participate and provide informed consent.\n\nExclusion Criteria:\n\n1. Inability to Provide Informed Consent: Patients who are unable or unwilling to provide consent.\n2. Limited life expectancy: patients with a life expectancy of less than 12 months due to other non-cardiac conditions.\n3. Liver Disease: patients with cirrhosis or significant liver dysfunction.\n4. Patients with contraindication to statin or other lipid-lowering therapy.\n5. Any condition that may interfere with the study process, including treatment adherence or follow-up appointments (e.g., dementia, alcohol abuse, severe debilitation, long distances required for follow-up, etc.).","18 Years",{"count":95,"type":22},1448,[25],"This multicenter randomized trial is designed to assess the efficacy of lipid-lowering therapy in patients undergoing percutaneous coronary intervention, comparing an Apolipoprotein B-targeted approach with a Low-Density Lipoprotein Cholesterol (LDL-C)-targeted approach. The primary outcomes are to evaluate the proportion of patients achieving lipid-lowering treatment goals at the 1-year follow-up between the two treatment strategies: Apolipoprotein B-based therapy versus LDL-C-based therapy.",[99,100,101,102],"Coronary Arterial Disease (CAD)","Percutaneous Coronary Intervention","LDL-cholesterol","Lipid Metabolism Disorders",[91,104,105,106],"PCI","Coronary artery disease","lipid lowering therapy","2024-10-13",{"date":109,"type":47},"2024-10-16",{"date":111,"type":22},"2025-01-01",{"date":113,"type":22},"2029-01-01",{"name":115,"class":54},"University Medical Center Ho Chi Minh City (UMC)",1,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":19,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":127,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},"100484406","intensive-lipid-lowering-in-patients-with-stemi-and-nstemi-germany-on-target-100484406","NCT05587621","Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)","\"Intensive Lipid-Lowering Therapy Guided by a Cloud-based Software System (CLIMEDO GmbH) in Patients With ST-Elevation and Non-ST-Elevation Myocardial Infarctions\" (Germany on Target)","GoT","Inclusion Criteria:\n\n* patients with ST- and Non-ST-elevation myocardial infarctions\n\nExclusion Criteria:\n\n* patient without informed concent\n* patients in cardiogenic shock\n* patients with contraindication to lipid-lowering therapy\n* patients on lipid-lowering medications on admission",{"count":126,"type":22},300,[25],"Intensive Lipid-Lowering Therapy guided by a cloud-based Software System (CLIMEDO GmbH) improves (European Society of Cardiolofgy\u002FEuropean Atherosclerosis Society) ESC\u002FEAS-guideline recommended LDL-cholesterol target attainment and adherence in patients with ST-Elevation Myocardial (STEMI) and Non-ST-Elevation Myocardial Infarctions (NSTEMI).",[130,131,101],"ST Elevation Myocardial Infarction","Non-ST Elevation Myocardial Infarction",[133],"STEMI, NSTEMI; LDL-C; target attainment","2024-03-05",{"date":136,"type":47},"2024-03-07",{"date":138,"type":22},"2024-04-01",{"date":140,"type":22},"2026-12-31",{"name":142,"class":54},"Jena University Hospital",10,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":154,"conditions":155,"keywords":158,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":116},"100498062","ldl-cholesterol-targets-in-older-patients-age75-years-with-ascvd-target-old-100498062","NCT05765370","LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)","LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With Atherosclerotic Cardiovascular Disease (TARGET OLD)","Inclusion Criteria:\n\n1. Men or women ≥75 years of age\n2. Diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD) with one or more of the following:\n\n   1. Diagnosis of coronary heart disease (one or more of the following criteria must be satisfied):\n\n      * Hospitalization for acute coronary syndrome\n      * Treatment or hospitalization for stable angina pectoris with documented ischemia on invasive or noninvasive testing\n      * History of myocardial infarction\n      * History of coronary revascularization procedure (eg, percutaneous coronary intervention \\[PCI\\] or coronary artery bypass graft surgery \\[CABG\\])\n      * Invasive diagnostic coronary angiography indicating \\>50% stenosis in at least one major epicardial coronary artery or CT-imaging (eg, CCTA\u002FMDCT) evidence of coronary atherosclerosis (\\>50% stenosis in at least two major epicardial coronary artery)\n   2. Diagnosis of atherosclerotic cerebrovascular or carotid disease (one or more of the following criteria must be satisfied):\n\n      * History of ischemic stroke or transient ischemic attack (TIA) confirmed by symptoms with a documented ischemic lesion on CT or MRI in the cerebral regions corresponding to the symptoms;\n      * Documented intracranial atherosclerotic stenosis on the basis of conventional cerebral angiography, magnetic resonance angiography, CT angiography, transcranial doppler ultrasound, and high-resolution MRI;\n      * Symptomatic carotid artery disease with ≥50% carotid arterial stenosis;\n      * Asymptomatic carotid artery disease with ≥70% carotid arterial stenosis per angiography or duplex ultrasound;\n      * History of carotid revascularization (catheter-based or surgical).\n   3. Diagnosis of atherosclerotic peripheral artery disease (one or more of the following criteria must be satisfied):\n\n      * History of aorto-iliac or peripheral arterial intervention (catheter-based or surgical).\n      * Prior non-traumatic amputation of a lower extremity due to peripheral artery disease\n      * History of intermittent claudication and one or more of the following:\n\n        1. An ankle\u002Farm blood pressure (BP) ratio \\\u003C 0.90, or\n        2. Significant peripheral artery stenosis (≥50%) documented by angiography, or by duplex ultrasound\n3. Baseline LDL-C level should be satisfied:\n\n   * Patients were required to have a baseline LDL-C level ≥100mg\u002FdL (2.6mmol\u002FL) if they were taking a regimen of lipid-lowering therapy \\\u003C4 weeks or they had not previously received lipid-lowering therapy.\n   * Patients were required to have a baseline LDL-C level ≥70mg\u002FdL (1.8mmol\u002FL) if they were on stable treatment with lipid-lowering therapy ≥4 weeks\n4. Signed written informed consent.\n\nExclusion Criteria:\n\n1. Subject was clinically unstable:\n\n   1. Hypotension, defined as sustained systolic blood pressure of \\\u003C90 mmHg due to cardiac failure with associated symptoms;\n   2. Unstable or severe pulmonary edema\u002Fdecompensated congestive heart failure;\n   3. Acute mitral regurgitation or acute ventricular septal defect;\n   4. Cardiogenic shock and\u002For need for mechanical\u002Fpharmacologic hemodynamic support\n   5. Ongoing Non-STEMI with biomarkers (cardiac troponin) still rising\n   6. Recent STEMI (≤7 days prior to randomization)\n   7. Recurrent symptoms of cardiac ischemia\n2. Moderate to severe heart failure (New York Heart Association \\[NYHA\\] Functional Classification III or IV) or last known left ventricular ejection farction (LVEF) \\\u003C40%.\n3. Severe renal dysfunction, defined as creatinine clearance \\\u003C30 mL\u002Fmin or estimated glomerular filtration (eGFR) rate less than 30 ml\u002Fmin\u002F1.73 m2, or requirement for peritoneal dialysis or hemodialysis for renal insufficiency.\n4. History of hemorrhagic stroke or unknown classified stroke.\n5. Uncontrolled or recurrent ventricular tachycardia (such as ventricular fibrillation, recurrent and highly symptomatic ventricular tachycardia, complete heart block, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia that are not controlled by medications).\n6. Uncontrolled hypertension (greater than 180 mm Hg systolic and\u002For greater than 110 mm Hg diastolic at randomization visit).\n7. History or clinical evidence of active liver disease or hepatic dysfunction, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 3 × upper limit of normal (ULN), or total bilirubin \\> 2 × ULN.\n8. Unexplained elevated creatine kinase (CK) concentration \\>5 × ULN or elevation due to known muscle disease.\n9. Planned or expected cardiac surgery, PCI or carotid stenting, or planned major noncardiac surgery during the study period. If angiography or revascularization is planned, patients may be screened and enrolled after all such planned procedures are completed.\n10. Active Malignancy (except nonmelanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma) including those patients requiring surgery, chemotherapy, and\u002For radiation in the past 3 years.\n11. Drug or alcohol abuse, and inability\u002Funwillingness to abstain from drug abuse and excessive alcohol consumption during the study.\n12. Severe, concomitant noncardiovascular disease that is expected to reduce life expectancy to \\\u003C3 years\n13. Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies), or receiving other investigational agent(s)\n14. Subject has received drugs via a systemic route that have known major interactions with background statin therapy (eg, itraconazole, ketoconazole, and other antifungal azoles, erythromycin, clarithromycin, or cyclosporine nefazodone) within 1 month prior to randomization or is likely to require such treatment during the study period.\n15. Recipient of any major organ transplant (eg, lung, liver, heart, bone marrow, renal)\n16. Subject likely to not be available to complete all protocol-required study visits or procedures, and\u002For to comply with all required study procedures (eg, Clinical Outcome Assessments) to the best of the subject and investigator's knowledge.\n17. Any uncontrolled or serious disease, or any medical or surgical condition (such as known active infection or major hematologic, renal, metabolic, gastrointestinal or endocrine dysfunction, or a chronic disease or infection \\[eg, HIV\\]), that may either interfere with participation in the clinical study and is not currently stable and appropriately managed in the judgment of the investigator, and\u002For put the subject at significant risk (according to investigator's judgment) if he\u002Fshe participates in the clinical study.\n18. Mental\u002Fpsychological impairment\u002Fneurocognitive disorder, or any other reason to expect patient difficulty in complying with the requirements of the study or understanding the goal and potential risks of participating in the study",{"count":152,"type":22},4200,[25],"To determine whether treating to an LDL-C target of 25 to \\\u003C70 mg\u002FdL is superior to an LDL-C target of 70 to \\\u003C100 mg\u002FdL with respect to major cardiovascular events (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) in patients aged ≥75 years with atherosclerotic cardiovascular disease (ASCVD).\n\nTo determine whether treating to an LDL-C target of 25 to \\\u003C70 mg\u002FdL is non-inferior to an LDL-C target of 70 to \\\u003C100 mg\u002FdL with respect to major safety events (hemorrhagic stroke, new-onset diabetes, muscle-related events, neurocognitive adverse events, new or recurrent cancer, cataract, or hepatic disorder \\[Alanine aminotransferase (ALT)\u002FAspartate aminotransferase (AST) \\>3× ULN, or total bilirubin \\>2× ULN\\]) in patients aged ≥75 years with ASCVD.",[156,157,35],"Atherosclerotic Cardiovascular Disease","Older Patients",[159,156,160,161,162,163,164],"LDL-C target","Older patients","Age≥75 years","Lipid-lowering therapy","Stain","PCSK9 inhibitor","2023-04-07",{"date":167,"type":47},"2023-04-10",{"date":169,"type":47},"2023-03-24",{"date":171,"type":22},"2026-12-24",{"name":173,"class":174},"China National Center for Cardiovascular Diseases","OTHER_GOV"]